Glycostem CEO Troels Jordansen is attending Inv€$tival Showcase in London, UK on 14 Nov 2022. Inv€$tival is an international showcase of early, growth stage and public life science and health technology companies.
Glycostem is going to present a poster at the SITC 37th Annual Meeting, held November 10-12, 2022, in Boston, MA, USA.
Title: Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia
Abstract Number: 245
Presentation and Session Information*
Annual Meeting Regular Poster Abstract Presenter: (245) Cord blood CD34+ stem cells are efficiently transduced with anti-CD19-CAR and expanded and differentiated into viveNK™ Natural Killer cells which display selective cytotoxicity against B-cell leukemia
11/10/2022 - 11/11/2022, 9:00 am - 9:00 pm
Presented by: Monica Raimo
Glycostem CDO Volker Huppert will be speaking at Cell Series UK conference on 7th - 8th November, 2022.
Glycostem CEO Troels Jordansen will present at the Onco Cell Therapy Summit Europe taken place on 2nd-3rd Nov 2022 in Amsterdam.
Date and time: 2nd Nov 2022 11:00 (CET)
Presentation title: Developing end-to-end, closed manufacturing of NK cell therapy from umbilical cord blood (UCB)- derived stem cells
• Set-up of production and implementing automation
• Exploration of how this process can reduce investment
Glycostem CDO Volker Huppert and CMO Kai Pinkernell are going to present at the Innate Killer Summit Europe.
20th Oct 2022 08:30 GMT+1, Volker Huppert:
Maximising Product Stability by Understanding Fundamental Elements of Stability to Advance Cryopreservation Protocols
20th Oct 2022 14:30 GMT+1 Kai Pinkernell:
Bringing Allogeneic NK cells into Clinical Trials for AML
Glycostem to participate 22nd Annual Biotech in Europe Forum (BEF), in-person event on 21st-22nd of September 2022 at Basel, Switzerland.